Advertisement

Picture Eurasanté BioFIT 2017 Strasbourg France November 600x60px
Document › Details

InflaRx N.V.. (11/8/17). "Press Release: InflaRx Announces Pricing of Initial Public Offering". Jena.

Region Region United States (USA)
Organisation Organisation Nasdaq Global Select Market
  Today Nasdaq Global Market
  Group Nasdaq OMX (Group)
Products Product investment banking
  Product 2 IFX-1 (InflaRx)
Index term Index term InflaRx–SEVERAL: investment, 201711 IPO $100m w 6.667m common shares at $15/share at Nasdaq Global Select Market
Persons Person Riedemann, Niels C. (InflaRx 200803 Managing Director + founder)
  Person 2 Gutjahr-Löser, Claudia (MC Services 201710– Managing Director before MorphoSys 2002–2017 + Cassiopeia + Deutsche Bank)
     


InflaRx, the biopharmaceutical company developing new therapeutics in the terminal complement space, today announced the pricing of its initial public offering of 6,667,000 common shares at an initial public offering price of $15.00 per common share, for total gross proceeds of approximately $100 million. In addition, InflaRx has granted the underwriters a 30-day option to purchase up to an additional 1,000,050 common shares at the public offering price, less underwriting discounts and commissions. All of the common shares are being offered by InflaRx. The shares are scheduled to begin trading on the NASDAQ Global Select Market on November 8, 2017 under the ticker symbol “IFRX.” The offering is expected to close on November 10, 2017, subject to customary closing conditions.

J.P. Morgan, Leerink Partners and BMO Capital Markets are acting as joint book-running managers for the offering.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on November 7, 2017. The offering will be made only by means of a prospectus, copies of which may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204; Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800) 808 7525, ext. 6132 or by email at syndicate@leerink.com; or BMO Capital Markets Corp., Attention: Equity Syndicate Department, 3 Times Square, New York, NY 10036, by telephone at (800) 414-3627, or by email at bmoprospectus@bmo.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.


About InflaRx:

InflaRx is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a.


Contacts:

InflaRx GmbH
Prof. Dr. Niels C. Riedemann - CEO
Email: info[at]inflarx.de
Tel: +49-3641-508180

MC Services AG
Dr. Claudia Gutjahr-Loeser
Email: inflarx[at]mc-services.eu
Tel: +49-89-210 2280

   
Record changed: 2017-11-13

Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 600x60px

More documents for InflaRx (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Eurasanté BioFIT 2017 Strasbourg France November 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px